Patient info Search Menu

Magnesium Trisilicate Compound tablets BP – patient leaflet, side effects, dosage

Updated:
Key facts
Status:
General sale (GSL)
Medicine strength:
250 mg + 120 mg
Contains active substances:

Patient leaflet - Magnesium Trisilicate Compound tablets BP

1. What Magnesium Trisilicate Tablets are and what they are used for

Magnesium Trisilicate Tablets contain two active

ingredients, magnesium trisilicate and hydrated aluminium oxide.

These are antacids which work by neutralising acid in your stomach.

These tablets are used to treat dyspepsia (heartburn or indigestion) and reflux. They can also help to heal duodenal ulcers.

2. What you need to know before you take Magnesium Trisilicate Tablets

Do not take Magnesium Trisilicate Tablets if:

  • You know you are allergic to magnesium trisilicate or aluminium oxide or to any of the other ingredients (these are listed in section 6)
  • You suffer from acute porphyria

    • You have a blood condition called

      hypophosphataemia (low concentraton of phosphate in the blood).

Warnings and Precautions

Check with your doctor before taking this medicine if:

  • You have kidney problems.

    Other medicines and Magnesium Trisilicate Tablets

    These tablets can affect some other medicines you may be taking, and they should not be taken at the same time of day as other medicines.

    Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines

    including any you have bought yourself. Particularly any of the following:

    • quinidine (for an irregular or fast heartbeat)
    • ACE inhibitors (for high blood pressure)
    • salicylates eg. aspirin
    • atazanavir or tipranavir (for HIV infection)
    • azithromycin, isoniazid, itraconazole, ketoconazole, methenamine, nitrofurantoin, rifampicin,

      tetracyclines, cephalosporins or flouroquinolones (to treat infections)

      • lithium, sulpiride or phenothiazines (for depression or mental illness)
      • barbiturates (sedatives)
      • bisphosphonates (for osteoporosis)
      • proguanil (to prevent malaria), chloroquine or hydroxychloroquine (to prevent malaria or treat

        rheumatoid arthritis or lupus (SLE))

        • deflazacort (a corticosteroid to treat allergic or inflammatory conditions)
        • mycophenolate (to prevent organ rejection)
        • penicillamine (for rheumatoid arthritis)
        • digoxin (for heart failure or irregular heartbeat)
        • dipyridamole (to prevent blood clots)
        • eltrombopag (to treat blood disorder)

          • erlotinib (to treat some types of cancer)
          • fexofenadine (an antihistamine)
          • gabapentin or phenytoin (to treat epilepsy or nerve pain)
          • lansoprazole (to treat ulcers)
          • levothyroxine (to treat a thyroid problem)
          • rosuvastatin (for high cholesterol)
          • ulipristal (an emergency contraception)
          • sodium or calcium polystyrene sulfate (to treat high

            levels of potassium in the blood)

            • iron preparations (to treat or prevent anaemia)
            • bile acids.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machinery

Magnesium Trisilicate Tablets should not affect your ability to drive or operate machinery.

Magnesium Trisilicate Tablets contain sucrose and lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Magnesium Trisilicate Tablets

Suck or chew before swallowing.

Always take this medicine exaxtly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The usual recommended dose is:

Adults:

Suck or chew one or two tablets when required, usually between meals and at bedtime. Do not take at the same time as other medicines. Do not take more than the dose stated above.

If you continue to have the same symptoms, or if you

find that you need to take the tablets frequently, go and see your doctor.

Children should not take these tablets.

If you take more tablets than you should

Speak to your doctor or pharmacist straightaway.

4. Possible side effects

Magnesium Trisilicate Tablets are suitable for most people if they are taken at the recommended dose, but, like all medicines they can sometimes cause side effects, although not everybody gets them. Diarrnoea and belching have been reported. Taken excessively over a long time this medicine may cause kidney stones.

Patients who have had stomach bypass operations or those who have kidney problems may experience hypermagnesaemia (an abnormally high level of magnesium in the blood). This can lead to muscle weakness, low blood pressure, changes in heart beat, drowsiness or confusion. In severe cases it may be very difficult to breath and the heart rate may slow.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Magnesium Trisilicate Tablets

Keep out of the sight and reach of children. Do not store above 25°C. Store in the original container.

Do not use the tablets after the expiry date shown on the label.

Take any left over back to your pharmacist to be destroyed. Do not throw away any medicine via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Magnesium Trisilicate Tablets contain

Each tablet contains 250 mg magnesium trisilicate and 120 mg hydrated aluminium oxide as the active ingredients. The other ingredients are sucrose, lactose, pregelatinised maize starch, potato starch, stearic acid and peppermint oil.

Read the package leaflet before use.

MA Holder and Distributor:

What Magnesium Trisilicate Tablets look like

The tablets are round and white. This pack contains 100 tablets.

Marketing authorisation holder:

Dalkeith Laboratories Ltd., 2 Park Street, Woburn, Bedfordshire, MK17 9PG, UK.

Manufacturer:

Surepharm Services Ltd., Ashby Road East, Burton upon Trent, Staffs, DE15 0YZ, UK.

Date of revision: December 2020.

If you would like the leaflet in a different format, please contact the licence holder at the above address.

Base Page

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk)

Last revision stated in the text: December 2020

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Magnesium Trisilicate Compound tablets BP

What these facts mean

Prescription needed?? No, general sale list medicine (GSL) – also sold outside pharmacies
Active substances? Aluminium hydroxide, Magnesium trisilicate
Strength? 250 mg + 120 mg
Pharmaceutical form? Oral tablet
Plain white, uncoated round tablet.
How is it taken? Oral
Excipients? Sucrose, Lactose, Pregelatinised Maize Starch, Potato Starch, Stearic Acid, Peppermint Oil
Pack sizes 100 tablet
Is it available?? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 5 years.
Storage Do not store above 25°C. Store in the original container.
Marketing authorisation? PL 51463/0130 (first authorised 16 November 2006)
Marketing authorisation holder? Kent Pharma UK Limited
Codes? GTIN 5039290001218 · BNF 01010100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.